Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial

Trials

Volumn 11, Issue , 2010, Pages

  Tadić, André ^a   Gorbulev, Stanislav ^a   Dahmen, Norbert ^a,b   Hiemke, Christoph ^a   Braus, Dieter F ^c   Röschke, Joachim ^d   van Calker, Dietrich ^e   Wachtlin, Daniel ^a   Kronfeld, Kai ^a   Gorbauch, Thorsten ^a   Seibert Grafe, Monika ^a   Lieb, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Clinic for Psychiatry and Psychotherapy   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d Clinic for Psychiatry and Psychotherapy   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; LITHIUM; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GERMANY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; COMPARATIVE STUDY; DRUG ADMINISTRATION; METHODOLOGY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; GERMANY; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77949380665     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-21     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 1994, Washington DC: American Psychiatric Association, American Psychiatric Association.
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacín C, Romera B, Taub N, Vollebergh WA, . ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica Supplement 2004, 420:21-27. ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project.
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, . National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). The Journal of the American Medical Association 2003, 289:3095-3105. National Comorbidity Survey Replication.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. Public Library of Science Medicine 2006, 3:e442. 1664601, 17132052.
5. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. Journal of Mental Health and Policy and Economics 2006, 9:87-98.
6. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003, 64:1465-1475.
7. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science Medicine Medicine 2008, 5:e45.
8. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008, 358:252-260. 10.1056/NEJMsa065779, 18199864.
9. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports 2007, 9:449-459. 10.1007/s11920-007-0061-3, 18221624.
10. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758. 10.1016/S0140-6736(09)60046-5, 19185342.
11. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005, 143:415-426.
12. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 1984, 41:782-786.
13. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry 1987, 44:259-264.
14. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ. WFSBP Task Force on Unipolar Depressive Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World Journal of Biological Psychiatry. 2007, 8:67-104.
15. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) Empfehlungen zur Therapie der Depression. Berlin 2006, 2, Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ).
16. Nationale Versorgungsleitline Depression Nationale Versorgungsleitline Depression., http://www.depression.versorgungsleitlinien.de
17. Deutsche Gesellschaft für Psychiatrie Psychotherapie und Nervenheilkunde Behandlungsleitlinie Affektive Erkrankungen. 2000, Heidelberg: Springer, Deutsche Gesellschaft für Psychiatrie Psychotherapie und Nervenheilkunde.
18. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000, 157(suppl 4):1-45. American Psychiatric Association.
19. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 2000, 157:1423-1428. 10.1176/appi.ajp.157.9.1423, 10964858.
20. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004, 29:566-579. 10.1038/sj.npp.1300341, 14627997.
21. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. The Journal of Clinical Psychiatry 2005, 66:148-158. 10.4088/JCP.v66n0201, 15704999.
22. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 2006, 26:56-60. 10.1097/01.jcp.0000195042.62724.76, 16415707.
23. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry 2006, 63:1217-1223. 10.1001/archpsyc.63.11.1217, 2211759, 17088502.
24. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. The Journal of Clinical Psychiatry 2007, 68:1195-1205. 10.4088/JCP.v68n0805, 17854243.
25. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. The Journal of Clinical Psychiatry 2003, 64:413-420.
26. Szegedi A, Jansen WT, van Willigenburg AP, Meulen E, Stassen HH, Thase ME. Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter-evidence from 6,562 patients. The Journal of Clinical Psychiatry 2009, 70:344-353. 10.4088/JCP.07m03780, 19254516.
27. Tadić A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, Hegerl U. Early improvement is a predictor of treatment outcome in patients with mild major minor or subsyndromal depression. Journal of Affective Disorders 2010, 120:86-93. 10.1016/j.jad.2009.04.014, 19428118.
28. Hamilton M. Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology 1967, 6:278-296.
29. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Archives of General Psychiatry 1991, 48:851-855.
30. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987, (Suppl 334):1-100.
31. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. The Journal of Clinical Psychiatry 2004, 65:1190-1196.
32. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. The Journal of Clinical Psychiatry 2002, 63:331-336.
33. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacolology 2007, 22:323-329.
34. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. The Journal of Clinical Psychiatry 2006, 67:1836-1855. 10.4088/JCP.v67n1203, 17194261.
35. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European Archives of Psychiatry and Clinical Neuroscience 2005, 255:387-400. 10.1007/s00406-005-0579-5, 15868067.
36. Crossley NA, Bauer M. Accelaration and Augmentation of Antidepressants with lithium for depressive disoders: 2 meta-analyses of randomized, placebo-controlled trials. The Journal of Clinical Psychiatry 2007, 68:935-940. 10.4088/JCP.v68n0617, 17592920.
37. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G, . Arbeitsgemeinschaft für Neuropsychopharmakologie und -pharmakopsychiatrie The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265. 10.1055/s-2004-832687, 15551191, Arbeitsgemeinschaft für Neuropsychopharmakologie und -pharmakopsychiatrie.
38. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M, . STAR*D Study Team Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. The New England Journal of Medicine 2006, 354:1231-1242. 10.1056/NEJMoa052963, 16554525, STAR*D Study Team.
39. Adli M, Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. The Journal of Clinical Psychiatry 2002, 63:782-790.
40. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. The Journal of Clinical Psychiatry 2007, 68:352-360. 10.4088/JCP.v68n0301, 17388703.
41. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophrenia Research 2008, 101:312-319. 10.1016/j.schres.2008.01.018, 18308513.
42. Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. Journal of Psychiatric Research 2008, 42:1176-1184. 10.1016/j.jpsychires.2008.02.002, 18348888.